LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,257 shares of the medical instruments supplier’s stock after selling 812 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in LeMaitre Vascular were worth $488,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after buying an additional 11,395 shares during the last quarter. Intech Investment Management LLC bought a new position in LeMaitre Vascular during the third quarter worth $377,000. Advisors Asset Management Inc. lifted its stake in LeMaitre Vascular by 180.2% during the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 1,191 shares during the last quarter. Quest Partners LLC bought a new position in LeMaitre Vascular during the third quarter worth $265,000. Finally, Victory Capital Management Inc. lifted its stake in LeMaitre Vascular by 23.3% during the third quarter. Victory Capital Management Inc. now owns 53,060 shares of the medical instruments supplier’s stock worth $4,929,000 after purchasing an additional 10,011 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LMAT has been the topic of several research analyst reports. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Lake Street Capital initiated coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. JMP Securities raised their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $107.97 on Monday. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 59.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.89. LeMaitre Vascular, Inc. has a one year low of $51.70 and a one year high of $108.09. The stock’s fifty day moving average is $93.85 and its 200-day moving average is $86.91.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is currently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.